Presagen’s Life Whisperer, an AI product to support IVF treatment, will be featured in three new clinical studies at the premier Asia Pacific fertility conference, ASPIRE 2023 in September 2023. ASPIRE will be held in the hometown of Presagen’s Australian offices, Adelaide, in South Australia.
Two of the three oral presentations relate to clinical studies conducted in collaboration with Ovation Fertility, who are now part of US Fertility, the largest fertility network in the US. The first presentation shows that AI can help standardize embryo assessment by reducing human subjectivity and variability. Standardization can help maintain quality of care, not only amongst different medical professionals with different levels of experience, but also between clinics in large clinic networks.
The second presentation shows that it is possible to combine two Life Whisperer AI algorithms, which look at different aspects of embryo quality, into a single score to make AI embryo assessment and selection more holistic and intuitive for embryologists. The single score combines Life Whisperer Viability and Life Whisperer Genetics AIs, which evaluate the likelihood that an embryo will lead to a pregnancy, and the likelihood that an embryo will be genetically normal (euploid), respectively. Although overlapping, these assessments analyze different parts of embryo quality and which do not always agree. The combined score is a practical approach to balance two separate quality assessments into a single measurement, while maintaining similar improvements in pregnancy outcomes and prediction of genetic integrity to that of each score independently.
The final, third presentation is an independent study conducted by Flinders Fertility in Adelaide, Australia, who have been using Life Whisperer commercially for over two years to support their patients’ IVF treatment. The study shows that combining the Life Whisperer Viability AI with manual embryo assessment can be synergistic. This could lead to further improvements in embryo selection and pregnancy outcomes for patients.
Life Whisperer will be exhibited at the event by its global distributor FujiFilm Irvine Scientific. Presagen will also be promoting its non-invasive, instant, low-cost and objective embryo assessment tools. These tools have been shown to improve pregnancy success rates and therefore reduce the time to pregnancy compared with current manual morphological grading*. Life Whisperer is authorized for sale in 47 countries globally.
The titles and summary of the three oral presentations are:
An artificial intelligence algorithm outperforms highly variable embryologist grading for predicting the likelihood of pregnancy outcome from embryo images
By Presagen/Life Whisperer (Australia, USA), Ovation/US Fertility (USA).
Presenter: Matthew (Tex) VerMilyea (Ovation/USF)
Summary: Embryologist evaluation of embryos is critical for ensuring successful pregnancy outcomes. Standard, manual evaluation is variable, subjective, and time-consuming. The aim of this study was to evaluate whether an artificial intelligence (AI) algorithm can standardize and improve embryo evaluation during IVF. The results of this study demonstrated the inherent variability and lack of objectivity associated with an embryologist’s evaluation of embryos. It highlights the benefits of accurate AI algorithms for standardizing embryo assessment.
Development of a combined artificial intelligence score for evaluating both embryo ploidy and viability to aid in embryo selection during IVF
By Presagen/Life Whisperer (Australia, USA), Ovation/US Fertility (USA)
Presenter: Sonya Diakiw (Presagen/Life Whisperer)
Summary: Artificial intelligence (AI) is being increasingly used for non-invasive evaluation of embryo quality during IVF. Previous studies described development of AI for selecting embryos likely to be euploid (genetics AI), or likely to lead to clinical pregnancy (viability AI), based on analysis of images of blastocysts on day 5 of development. The aim of this study was to determine if a combination of these AI scores could be used to effectively evaluate both outcomes. The results of the study shown that a combined AI score that can evaluate both embryo ploidy and viability simultaneously is useful for selecting preferred embryos for analysis or transfer. These results suggest that it is feasible to generate a single score for evaluating overall embryo quality using a non-invasive approach.
Improved time to pregnancy when combing an artificial intelligence score and morphology grading for embryo selection during IVF
By Flinders Fertility (Australia)
Presenter: Ashleigh Storr (Flinders Fertility)
Summary: Embryo selection is critical in determining IVF success yet continues to be challenging due to the subjectivity of morphology grading methods, especially when grading fair/average quality embryos. Improving embryo selection could optimize implantation rates and minimize financial/emotional burden on patients. Artificial Intelligence (AI) algorithms represent promising, non-invasive methods of standardizing embryo grading and potentially increasing IVF success rates. This study assessed whether an AI algorithm (Life Whisperer Viability) for evaluating the likelihood of clinical pregnancy improves time to pregnancy (TTP) when compared to or combined with standard morphology grading. The results of this study showed that LWV improved embryo ranking and reduction in the estimated average number of transfers needed to achieve clinical pregnancy. Furthermore, evaluation of TTP supports the combined use of LWV+Gardner grading, showing that they work synergistically to further improve ranking performance when selecting average quality embryos that may be transferred in later cycles.
* Using simulated cohort ranking analysis.
Life Whisperer is a world-leader in the application of AI in IVF. The Life Whisperer Viability and Genetics AI-based embryo assessment tools are the first to be commercialized in a series of applications that encompass the complete IVF journey. Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally. Life Whisperer is being used in IVF clinics around the world.
Presagen is an AI healthcare company that is changing the way clinics, patients, and medical data from around the world are connected through AI. Its platform, The Social Network for Healthcare, connects clinics and patients globally, and enables collaboration and data sharing to create scalable AI healthcare products that are affordable and accessible for all. The decentralized network democratizes the creation of AI products, promotes collaboration through incentives, and protects data privacy and ownership. With a focus on improving Women’s Health outcomes globally, Presagen’s first product, Life Whisperer, is being used by IVF clinics globally to improve pregnancy outcomes for couples struggling with fertility. With a vision of creating the largest network of clinics, patients, and medical data from around the world, Presagen is driving the future of AI Enhanced Healthcare.
With a focus on improving Women’s Health outcomes globally, Presagen’s first product, Life Whisperer, is being used by IVF clinics globally to improve pregnancy outcomes for couples struggling with fertility. With a vision of creating the largest network of clinics, patients, and medical data from around the world, Presagen is driving the future of AI Enhanced Healthcare.